Absci rose 186.0% from $2.86 to $8.18, ahead of the S&P 500's +10.2%. Its worst day was Jul 16 (−15.7%), and its low came Mar 12 at $2.30.
Story events cover the past 12 months · Times ET
Nov 19, 2025 – Nov 18, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Absci closed at its lowest level of the year, 19.6% below where the year started.
−6.1% · S&P 500 −1.5%
EPS of $-0.20 missed the $-0.17 estimate on $650,000.00 revenue (est. $2.3M).
−3.0% · S&P 500 +0.6%
Absci shares rose 23.1%, while the S&P 500 rose 0.2%.
+23.1% · S&P 500 +0.2%
EPS of $-0.19 beat the $-0.20 estimate on $215,000.00 revenue (est. $1.6M).
+2.6% · S&P 500 +0.8%
Absci shares rose 23.6%, while the S&P 500 rose 0.4%.
+23.6% · S&P 500 +0.4%
Estimated half-life of at least 65 days supports potential for ABS-201 targeted dosing interval of two or three injections over six-month periodFirst multiple ascending dose (MAD) of ABS-201 in cohort of androgenetic
+36.0%, the year's best day, on 38M shares, the year's heaviest volume · S&P 500 0.0%
EPS of $-0.21 missed the $-0.19 estimate on $318,000.00 revenue (est. $1.3M).
+1.0% · S&P 500 +0.3%
Absci closed at its highest level of the year, 323.1% above where the year started.
+1.9% · S&P 500 −0.4%
EPS of $-0.19 beat the $-0.19 estimate on $304,000.00 revenue (est. $991,360.00).
−9.7% · S&P 500 −0.4%
Where it ended: a close of $8.18 on Nov 18, 2026.
Nothing in the past 12 months.
All ABSI dividend history